Governance & diversity

Corporate structure

Reserve Meds operates as a cross-border specialty pharmacy platform. Our US pharmacy operations are conducted by Altima Care, a US-licensed specialty wholesaler and DSCSA-compliant authorized distributor. Holding and IP are separated into distinct entities to protect patient data and operational independence. Detailed entity disclosures are available to regulators, counterparties, and journalists on request via [email protected].

Board & oversight

Our governance model includes a founder-led executive team, an independent clinical advisory panel, and retained outside regulatory counsel in the US and in each priority destination country. Material decisions — new country launches, acquisitions, capital events, and changes to our access policies — require documented sign-off from the CEO, clinical advisory lead, and outside counsel.

Clinical advisory panel

Reserve Meds maintains a panel of 8–12 licensed physicians across our priority specialties and geographies. The panel reviews our clinical content, advises on edge-case access requests, and provides independent input on our ethics posture. Panel members serve two-year terms, disclose all industry relationships, and are compensated at fair market value for their time.

Diversity, equity, and access

Our mission — to help every patient access the medicine they need regardless of where they live — requires that we operate across wide differences in language, income, and healthcare infrastructure. We commit to:

• Publishing core patient-facing content in English, Arabic, Hindi, and Urdu, with additional languages added as we expand.
• Offering tiered, case-specific pricing that accounts for patient context — we do not apply a single list price globally.
• Operating a non-discrimination policy in intake: we do not decline cases on the basis of nationality, religion, gender, sexual orientation, or disability. We decline cases only on the basis of clinical safety, regulatory feasibility, or sourcing compliance.
• Publishing annually an access-equity report summarizing the geographic, linguistic, and therapeutic-area distribution of the patients we served.

Data & privacy governance

Patient data is handled under HIPAA in the US, under GDPR where applicable, and under the destination country's privacy framework. Our data retention policy, breach-response playbook, and subject-access-request workflow are documented in our privacy policy and available on request.

Reporting & accountability

Any patient, physician, partner, employee, or member of the public may report a governance concern to [email protected]. Concerns involving clinical safety, regulatory compliance, or financial integrity are escalated to outside counsel and, where appropriate, to the relevant regulatory authority. We publish an annual governance summary documenting the categories of concerns received and how they were resolved.

Reviewed 2026-04-22 by Reserve Meds's AI clinical and regulatory review agents. Next scheduled review: 2026-10-22.